$Barinthus Biotherapeutics (BRNS.US)$ NEWS Barinthus Bio Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus (HPV) Infections Barinthus Bio announced positive topline data from the Phase 1b/2 APOLLO trial of VTP-200 in persistent high-risk human papillomavirus (HPV) infections. VTP-200 demonstrated positive trends in clearance rates for both high-risk HPV and cervical lesions in groups receiving the highest ChAdOx dose. However, there was no...
Barinthus Biotherapeutics股票讨论区
在 VTP-300 公布慢性乙型肝炎病毒感染的积极中期数据之后,Barinthus Bio宣布了战略管道优先顺序
根据正在进行的二期试验的积极中期数据,Barinthus Biotherapeutics宣布计划确定其产品线的优先顺序,将重点放在用于慢性乙型肝炎(CHB)的 VTP-300 和用于乳糜泻的 VTP-1000 上。该公司将进行重组,裁员25%,并预计将现金流扩大至...
根据初步的治疗结束数据,Arbutus说,该疗法使治疗后的随访期间乙型肝炎表面抗原水平保持在较低水平。
...
两份摘要重点介绍了公司主要的乙型肝炎资产,将以海报和口头陈述的形式呈现。
在今年早些时候削减摘要数据之后,将在EASL上公布的更成熟的中期数据可能表明潜在的功能治愈率。
$Iovance Biotherapeutics (IOVA.US)$第 2 阶段
$Supernus Pharmaceuticals (SUPN.US)$第 2a 阶段
$BRANDES INTERNATIONAL ETF (BINV.US)$第 2a 阶段
$MorphoSys (MOR.US)$第 2 阶段
$Nuvation Bio (NUVB.US)$第 2 阶段
$ALX Oncology (ALXO.US)$第 2 阶段
$BioXcel Therapeutics (BTAI.US)$第 2 阶段
$Purple Biotech (PPBT.US)$第 2 阶段
$Arcus Biosciences (RCUS.US)$第 2 阶段
$Medicenna Therapeutics (MDNAF.US)$第 2b 阶段
$Affimed NV (AFMD.US)$第 2 阶段
$Barinthus Biotherapeutics (BRNS.US)$第 2b 阶段...
1 分钟前,美国东部时间下午 4:10
通过环球新闻专线
• 符合主要安全终点;VTP-200 总体耐受性良好,无治疗相关的 3 级或更高等级不良事件 (AE) 或严重不良事件 (SAE)。
• 高风险(小时)HPV(60%,第 2 组)和宫颈病变(67%,第 2 组和...
NEWS
Barinthus Bio Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus (HPV) Infections
Barinthus Bio announced positive topline data from the Phase 1b/2 APOLLO trial of VTP-200 in persistent high-risk human papillomavirus (HPV) infections. VTP-200 demonstrated positive trends in clearance rates for both high-risk HPV and cervical lesions in groups receiving the highest ChAdOx dose. However, there was no...
暂无评论